Статья

Breathomics can discriminate between anti IgE-treated and non-treated severe asthma adults

Giuseppe SantiniPharmacology, Catholic University of the Sacred HeartStefano Di CarloComputer Engineering, Polytechnic of TurinAlfredo BensoComputer Engineering, Polytechnic of TurinNadia MoresPharmacology, Catholic University of the Sacred HeartPaul BrinkmanRespiratory Medicine, Academic Medical Centre, University of AmsterdamSalvatore ValenteInternal Medicine and Geriatrics, Catholic University of the Sacred HeartPaolo MontuschiComputer Engineering, Polytechnic of TurinFrancesco MacagnoInternal Medicine and Geriatrics, Catholic University of the Sacred HeartGianfranco PolitanoComputer Engineering, Polytechnic of TurinAriane H. WagenerRespiratory Medicine, Academic Medical Centre, University of AmsterdamAruna T. BansalBiostatistics, Acclarogen LtdHugo KnobelPhysical Chemistry, Philips Research LaboratoriesAnton VinkPhysical Chemistry, Philips Research LaboratoriesNicholas J. W. RattrayRespiratory Medicine, University of ManchesterMarco SantonicoElectronic Engineering, Università Campus Bio-MedicoGiorgio PennazzaElectronic Engineering, Università Campus Bio-MedicoYuanyue WangPhysical Chemistry, Philips Research LaboratoriesIldikó HorváthRespiratory Medicine, Semmelweis UniversityRatko DjukanovićRespiratory Medicine, University of SouthamptonRiccardo PolosaInternal Medicine, University of CataniaStephen J. FowlerRespiratory Medicine, University of ManchesterPascal ChanezRespiratory Medicine, University of MarseilleKian Fan ChungRespiratory Medicine, Imperial CollegePeter J. SterkRespiratory Medicine, Academic Medical Centre, University of AmsterdamU-BIOPRED Study GroupPharmacology, Catholic University of the Sacred Heart

2015en

ABI

Аннотация

Rationale: Omalizumab, an anti-IgE monoclonal antibody, is indicated in adults with severe persistent allergic asthma. Exhaled molecular markers can provide phenotypic information in asthma. Objectives: Determine whether adults with severe asthma on omalizumab (anti-IgE+) have a different breathprint compared with those who were not on anti-IgE therapy (anti-IgE-) as assessed by eNoses and gas chromatography/mass spectrometry (GC/MS) (breathomics). Methods: This was a cross-sectional analysis of the U-BIOPRED adult cohort. Severe asthma was defined by IMI-criteria [Bel, Thorax 2011]. Anti-IgE+ patients were on a regular treatment with s.c. omalizumab (150-375 mg) every 2-4 weeks. Exhaled volatile compounds trapped on adsorption tubes were analysed by a centralized eNose platform (Owlstone Lonestar, two Cyranose 320, Comon Invent, Tor Vergata TEN), including a total of 190 sensors, and GC/MS. Recursive feature elimination (http://topepo.github.io/caret/rfe.html) was used for feature selection and random forests, more robust to overfitting, for classification. Results: 9 anti-IgE+ (females/males 2/7, age 52.6±16.3 years, mean±SD, 1/2/6 current/ex/nonsmokers, pre-bronchodilator FEV1 70.6±21.1% predicted value) and 30 anti-IgE- patients (18/12 females/males, age 53.2±14.2 years, 0/16/14 current/ex/nonsmokers, pre-bronchodilator FEV1 59.6±30.7% predicted value) were studied. Accuracy of classification is shown in Table 1. Conclusions: Preliminary results suggest that breathomics can distinguish between anti-IgE+ and anti-IgE- severe asthma patients.

Перевод пока недоступен

Темы

Advanced Chemical Sensor Technologies

Идентификаторы

DOI: 10.1183/13993003.congress-2015.oa1463

Цитирования и источники

Цитирований: 0Использованных источников: 0

Показатели — AkademScholar